This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Patent on Ingenus Pharma cancer-fighting injection is invalid, US judge finds

By Melissa Ritti ( May 12, 2025, 17:08 GMT | Insight) -- Recitation of a “stable” formulation of the anti-cancer injectable cyclophosphamide doomed an Ingenus Pharmaceuticals patent on Friday, with the term deemed indefinite. In the same decision, a US judge in Illinois denied the patent owner's request for a summary judgment of infringement. That not only clears a path for Nexus Pharmaceuticals to enter the market with its FDA-approved generic, but also leaves a Dr. Reddy's subsidiary — who last summer agreed to commercialize Ingenus' product in the US — in limbo.Nexus Pharmaceuticals’ efforts to compete in the anti-cancer arena took a big step forward Friday when a patent associated with injectable cyclophosphamide was declared invalid....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections